The CANVAS Program had a higher proportion of insulin use at baseline compared with other major trials, suggesting a higher proportion of participants with more complex type 2 diabetes mellitus, yet still reported favourable outcomes in this subgroup of participants. The gene discussed is INS; the disease is type 2 diabetes mellitus.